- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Concomitant renal dysfunction mitigates clinical benefit of milrinone in cardiogenic shock patients: JACC study
Cardiogenic shock is associated with poor clinical outcomes. There is a paucity of prospective data examining the efficacy and safety of different inotropic agents in patients with cardiogenic shock and renal dysfunction. Although, the DOREMI trial demonstrated no difference between the two inotropic agents dobutamine and milrinone, but a recently conducted post hoc analysis of this trial shows that a potential clinical benefit of milrinone vs dobutamine in cardiogenic shock could be attenuated by development of AKI (acute kidney injury).
The authors stratified the DOREMI trial population based on both baseline renal dysfunction and the development of AKI and examined clinical outcomes with milrinone compared to dobutamine after stratification based on baseline estimated glomerular filtration rate (eGFR) 60 ml/min/1.73 m2and AKI.
The primary outcome was the composite of in-hospital death from any cause, resuscitated cardiac arrest, receipt of a cardiac transplant or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke, or initiation of renal replacement therapy.
Most patients had AKI—124 of the 192 subjects enrolled. Main clinical findings included the fact that, in the stratum of patients with cardiogenic shock without AKI, milrinone was associated with better outcomes than dobutamine.
Such an effect was not observed in cardiogenic shock patients with AKI, where there was no difference between the strategies.
Baseline renal function did not appear to modulate the treatment effect of milrinone compared to dobutamine. However, there was an interaction between AKI and the treatment effect of milrinone vs dobutamine on the primary outcome and death. This interaction was characterized by a lower risk of the primary outcome and death with milrinone compared to dobutamine in patients without, but not with, AKI. (Figure 1)
The present analysis suggests a possible heterogeneity in the treatment effect of milrinone compared to dobutamine on clinical outcomes in relation to AKI. Compared to dobutamine, milrinone was associated with reduced rates of the primary outcome and death in the stratum of patients without AKI.
Exploring the role of individualized patient care, including patients with renal dysfunction, to improve clinical outcomes in cardiogenic shock should be a research priority.
Source: JACC Advances: JACC Adv. 2023 Jul, 2 (5) 100393
MBBS, MD , DM Cardiology
Dr Abhimanyu Uppal completed his M. B. B. S and M. D. in internal medicine from the SMS Medical College in Jaipur. He got selected for D. M. Cardiology course in the prestigious G. B. Pant Institute, New Delhi in 2017. After completing his D. M. Degree he continues to work as Post DM senior resident in G. B. pant hospital. He is actively involved in various research activities of the department and has assisted and performed a multitude of cardiac procedures under the guidance of esteemed faculty of this Institute. He can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751